Resource Summary Report

Generated by FDI Lab - SciCrunch.org on Apr 29, 2025

TMD8

RRID:CVCL_A442
Type: Cell Line

Proper Citation

(RRID:CVCL_A442)

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_A442

Proper Citation: (RRID:CVCL_A442)

Sex: Male

Defining Citation: PMID:16780947, PMID:20054396, PMID:21179087, PMID:23257783, PMID:23292937, PMID:25485619, PMID:26589293, PMID:26787899, PMID:27566572, PMID:29416618, PMID:29666304

Comments: Omics: Transcriptome analysis by RNAseq., Omics: Transcriptome analysis by microarray., Omics: SNP array analysis., Omics: Deep exome analysis., Omics: Array-based CGH., Characteristics: Genetically heterogeneous, consists of 3 subclones (PubMed=27566572)., Population: Japanese.

Category: Cancer cell line

Name: TMD8

Synonyms: TMD-8, Tokyo Medical and Dental university 8

Cross References: EFO:EFO_0006496, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-4956, BioGRID_ORCS_Cell_line:748, cancercelllines:CVCL_A442, ChEMBL-Cells:CHEMBL4295480, ChEMBL-Targets:CHEMBL4296503, Cosmic:1486587, Cosmic:1945194, Cosmic:2129635, EGA:EGAS00001000610, EGA:EGAS00001002554, GEO:GSM1059801, GEO:GSM1374963, GEO:GSM1527304, GEO:GSM1527305, GEO:GSM1527306, GEO:GSM1527307, GEO:GSM1527308, GEO:GSM1527309, GEO:GSM1890021, GEO:GSM1890022, GEO:GSM1890023, GEO:GSM1890024, GEO:GSM2037048, GEO:GSM2037049, PharmacoDB:TMD8_1600_2019, Progenetix:CVCL_A442, PubChem_Cell_line:CVCL_A442, Wikidata:Q54972694

ID: CVCL_A442

Record Creation Time: 20250131T202812+0000

Record Last Update: 20250131T204800+0000

Ratings and Alerts

No rating or validation information has been found for TMD8.

No alerts have been found for TMD8.

Data and Source Information

Source: Cellosaurus

Usage and Citation Metrics

We found 20 mentions in open access literature.

Listed below are recent publications. The full list is available at FDI Lab - SciCrunch.org.

Pieper NM, et al. (2024) Inhibition of bromodomain and extra-terminal proteins targets constitutively active NF?B and STAT signaling in lymphoma and influences the expression of the antiapoptotic proteins BCL2A1 and c-MYC. Cell communication and signaling : CCS, 22(1), 415.

Choi J, et al. (2024) Molecular targets of glucocorticoids that elucidate their therapeutic efficacy in aggressive lymphomas. Cancer cell, 42(5), 833.

Wu Y, et al. (2024) Translational modelling to predict human pharmacokinetics and pharmacodynamics of a Bruton's tyrosine kinase-targeted protein degrader BGB-16673. British journal of pharmacology.

Phelan JD, et al. (2024) Response to Bruton's tyrosine kinase inhibitors in aggressive lymphomas linked to chronic selective autophagy. Cancer cell, 42(2), 238.

Eken JA, et al. (2024) Antigen-independent, autonomous B cell receptor signaling drives activated B cell DLBCL. The Journal of experimental medicine, 221(5).

Li W, et al. (2024) Bruton's Tyrosine Kinase Inhibitors with Distinct Binding Modes Reveal Differential Functional Impact on B-Cell Receptor Signaling. Molecular cancer therapeutics, 23(1), 35.

Bolomsky A, et al. (2024) IRF4 requires ARID1A to establish plasma cell identity in multiple myeloma. Cancer cell, 42(7), 1185.

Johnson Z, et al. (2023) IOA-244 is a Non-ATP-competitive, Highly Selective, Tolerable PI3K Delta Inhibitor That Targets Solid Tumors and Breaks Immune Tolerance. Cancer research communications, 3(4), 576.

Rodina A, et al. (2023) Systems-level analyses of protein-protein interaction network dysfunctions via epichaperomics identify cancer-specific mechanisms of stress adaptation. Nature communications, 14(1), 3742.

Delage L, et al. (2023) BTG1 inactivation drives lymphomagenesis and promotes lymphoma dissemination through activation of BCAR1. Blood, 141(10), 1209.

Venturutti L, et al. (2023) An Aged/Autoimmune B-cell Program Defines the Early Transformation of Extranodal Lymphomas. Cancer discovery, 13(1), 216.

Scheich S, et al. (2023) Targeting N-linked Glycosylation for the Therapy of Aggressive Lymphomas. Cancer discovery, 13(8), 1862.

Roider T, et al. (2021) The impact of SAMHD1 expression and mutation status in mantle cell lymphoma: An analysis of the MCL Younger and Elderly trial. International journal of cancer, 148(1), 150.

Eisenmann ED, et al. (2021) Intentional Modulation of Ibrutinib Pharmacokinetics through CYP3A Inhibition. Cancer research communications, 1(2), 79.

Dersh D, et al. (2021) Genome-wide Screens Identify Lineage- and Tumor-Specific Genes Modulating MHC-I- and MHC-II-Restricted Immunosurveillance of Human Lymphomas. Immunity, 54(1), 116.

Dietz A, et al. (2020) Proteasome inhibitors and Smac mimetics cooperate to induce cell death in diffuse large B-cell lymphoma by stabilizing NOXA and triggering mitochondrial apoptosis. International journal of cancer, 147(5), 1485.

Yan P, et al. (2020) Molecular Stressors Engender Protein Connectivity Dysfunction through Aberrant N-Glycosylation of a Chaperone. Cell reports, 31(13), 107840.

Huang HT, et al. (2018) A Chemoproteomic Approach to Query the Degradable Kinome Using a Multi-kinase Degrader. Cell chemical biology, 25(1), 88.

Lionakis MS, et al. (2017) Inhibition of B Cell Receptor Signaling by Ibrutinib in Primary CNS Lymphoma. Cancer cell, 31(6), 833.

Reddy A, et al. (2017) Genetic and Functional Drivers of Diffuse Large B Cell Lymphoma. Cell, 171(2), 481.